Pag. 57-59 [prev][index][next]
Azacytidine: first therapeutic opportunity for myelodysplastic syndromes
C. Finelli, C. Bosi, G. Martinelli, M. Baccarani
Istituto di Ematologia “L. & A. Seragnoliâ€, Università di Bologna, Italy
Myelodysplastic syndromes (MDS) are clonal disorders characterized by ineffective hematopoiesis, wich can lead either to fatal cytopenia or acute myelogenous leukemia (AML). During the last 14 years, important progress has been made in the understanding of the biology and prognosis of MDS; risk-adapted treatment strategies were estabilished, according to the median age (60-75 years ) of MDS patients and the individual history of the desease (number of cytopenias, cytogenetic changes, transfusion requirements).
[>Read full article in PDF]